
    
      Patients with end stage liver disease that receive a liver transplant will be studied to
      determine if novel serum and urine biomarkers (serum cystatin C, urine interleukin-18 [IL-18]
      and urine neutrophil gelatinase associated lipocalin [NGAL]) can predict the outcome measures
      listed above.
    
  